Hemab Therapeutics Cash Flow Statement
NASDAQ: COAGHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Hemab Therapeutics has no annual cash flow statement on file yet, so quarterly figures are shown instead.
Hemab Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Hemab Therapeutics generated -$22.6 million of operating cash flow and spent $23,000 on capital expenditures. That left free cash flow of -$22.7 million.
Summary generated from market data by MetaCap's automated system. Methodology
Hemab Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Net Income | -24.15M | -22.69M | -12.21M | -15.31M |
| Net Income growth (YoY) | — | — | — | — |
| Depreciation & Amortization | 75.00K | 73.00K | 77.00K | 75.00K |
| Change in Working Capital | 550.00K | -52.00K | -2.32M | 2.88M |
| Operating Cash Flow | -22.64M | -21.58M | -15.33M | -13.03M |
| Capital Expenditures | -23.00K | -112.00K | 0 | -16.00K |
| Investing Cash Flow | -107.44M | -15.85M | 21.50M | -5.99M |
| Financing Cash Flow | 317.58M | -460.00K | -30.00K | -29.00K |
| Net Change in Cash | 187.51M | -38.11M | 6.14M | -19.06M |
| Free Cash Flow | -22.66M | -21.70M | -15.33M | -13.05M |
This table shows 4 quarterly periods of Hemab Therapeutics's cash flow statement, from Q2 2026 back to Q? 2025, across 9 line items including net income, depreciation & amortization, change in working capital. Values in USD; B = billions, M = millions. Fiscal periods follow COAG's reporting calendar. What is a cash flow statement?